| Human immunodeficiency virus I infection
Complera vs Norvir
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Complera vs Norvir with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNorvir has a higher rate of injection site reactions vs Complera based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Norvir but not Complera, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Complera
Norvir
At A Glance
Oral
Once daily
NRTI/NNRTI fixed-dose combination
Oral
Twice daily
HIV protease inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet orally once daily with food for adults and pediatric patients weighing at least 35 kg; not recommended in patients with estimated creatinine clearance below 50 mL/min.
Pregnancy One tablet once daily may be continued in virologically suppressed patients (HIV-1 RNA less than 50 copies/mL); monitor viral load closely due to lower rilpivirine exposures during pregnancy.
Rifabutin coadministration Add one additional 25 mg rilpivirine (Edurant) tablet once daily with a meal for the duration of rifabutin coadministration.
Human immunodeficiency virus I infection (Adults) 600 mg twice daily by mouth with meals; initiate at 300 mg twice daily and increase by 100 mg q2-3 days to minimize adverse events.
Human immunodeficiency virus I infection (Pediatrics >1 month) 350-400 mg/m2 twice daily by mouth with meals, not to exceed 600 mg twice daily; initiate at 250 mg/m2 twice daily and increase by 50 mg/m2 q2-3 days.
Contraindications
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with dexamethasone (systemic, more than a single dose)
- Coadministration with St John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (e.g., dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
- Known hypersensitivity (e.g., TEN or Stevens-Johnson syndrome) to ritonavir or any excipient
- Co-administration with drugs highly dependent on CYP3A for clearance with potential for serious or life-threatening reactions: alfuzosin, ranolazine, amiodarone, dronedarone, flecainide, propafenone, quinidine, voriconazole, colchicine (renal/hepatic impairment), lurasidone, pimozide, dihydroergotamine, ergotamine, methylergonovine, cisapride, lovastatin, simvastatin, lomitapide, sildenafil (Revatio for PAH), triazolam, oral midazolam
- Co-administration with potent CYP3A inducers associated with potential loss of virologic response: apalutamide, St. John's Wort (hypericum perforatum)
Adverse Reactions
Most common (>=2%) Depressive disorders, headache, insomnia, abnormal dreams, dizziness, nausea, rash
Serious Severe acute exacerbations of hepatitis B, skin and hypersensitivity reactions, hepatotoxicity, depressive disorders, new onset or worsening renal impairment, bone loss and mineralization defects, lactic acidosis/severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Weight gain, severe skin and hypersensitivity reactions including DRESS, nephrotic syndrome, allergic reaction including angioedema, lactic acidosis, pancreatitis, rhabdomyolysis, osteomalacia, acute renal failure, Fanconi syndrome
Most common (>=1%) Diarrhea, nausea, vomiting, abdominal pain, paresthesia (including oral), rash, fatigue/asthenia, dysgeusia, coughing, arthralgia, back pain, dizziness, pruritus, myalgia, flushing, hypertriglyceridemia, peripheral neuropathy, oropharyngeal pain
Serious Hepatotoxicity, pancreatitis, allergic reactions/hypersensitivity
Postmarketing Dehydration, AV block (first-, second-, third-degree), right bundle branch block, Cushing's syndrome, adrenal suppression, seizure, nephrolithiasis, toxic epidermal necrolysis
Pharmacology
COMPLERA is a fixed-dose combination antiretroviral containing emtricitabine (nucleoside reverse transcriptase inhibitor), rilpivirine (non-nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (nucleotide reverse transcriptase inhibitor); each component inhibits HIV-1 reverse transcriptase through distinct mechanisms to suppress viral replication.
Ritonavir is a peptidomimetic inhibitor of the HIV-1 protease that renders the enzyme incapable of processing the Gag-Pol polyprotein precursor, leading to production of non-infectious immature HIV particles; it also potently inhibits CYP3A and, to a lesser extent, CYP2D6, significantly affecting plasma concentrations of many co-administered drugs.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Complera
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Norvir
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Complera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Norvir
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Complera
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Norvir
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CompleraView full Complera profile
NorvirView full Norvir profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.